A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.
Piringer, G, Fridrik, M, Fridrik, A, Leiherer, A, Zabernigg, A, Greil, R, Eisterer, W, Tschmelitsch, J, Lang, A, Frantal, S, Burgstaller, S, Gnant, M, Thaler, J. Support Care Cancer. 2018, 26(4):1345-1352.
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.
Schommers, P, Gillor, D, Hentrich, M, Wyen, C, Wolf, T, Oette, M, Zoufaly, A, Wasmuth, JC, Bogner, JR, Müller, M, Esser, S, Schleicher, A, Jensen, B, Stoehr, A, Behrens, G, Schultze, A, Siehl, J, Thoden, J, Taylor, N, Hoffmann, C. Haematologica. 2018.
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia.
Huemer, F, Weiss, L, Faber, V, Neureiter, D, Egle, A, Geissler, K, Voskova, D, Zebisch, A, Burgstaller, S, Pichler, A, Stauder, R, Sperr, W, Lang, A, Pfeilstöcker, M, Machherndl-Spandl, S, Stampfl, M, Greil, R, Pleyer, L. Wien Klin Wochenschr. 2018.
PET-guided treatment in patients with advanced-stage Hodgkins lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Borchmann, P, Goergen, H, Kobe, C, Lohri, A, Greil, R, Eichenauer, DA, Zijlstra, JM, Markova, J, Meissner, J, Feuring-Buske, M, Hüttmann, A, Dierlamm, J, Soekler, M, Beck, HJ, Willenbacher, W, Ludwig, WD, Pabst, T, Topp, MS, Hitz, F, Bentz, M, Keller, UB, Kühnhardt, D, Ostermann, H, Schmitz, N, Hertenstein, B, Aulitzky, W, Maschmeyer, G, Vieler, T, Eich, H, Baues, C, Stein, H, Fuchs, M, Kuhnert, G, Diehl, V, Dietlein, M, Engert, A. Lancet. 2018, 390(10114): 2790-2802.
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino, E, Benedetti, D, Herman, SEM, Ten Hacken, E, Ahn, IE, Chaffee, KG, Rossi, FM, Dal Bo, M, Bulian, P, Bomben, R, Bayer, E, Härzschel, A, Gutjahr, JC, Postorino, M, Santinelli, E, Ayed, A, Zaja, F, Chiarenza, A, Pozzato, G, Chigaev, A, Sklar, LA, Burger, JA, Ferrajoli, A, Shanafelt, TD, Wiestner, A, Del Poeta, G, Hartmann, TN, Gattei, V, Zucchetto, A. J Exp Med. 2018.
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.
Bolger, GT, Licollari, A, Tan, A, Greil, R, Pleyer, L, Vcelar, B, Majeed, M, Sordillo, P. Anticancer Res. 2018, 38(1): 12-130.
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Wöll, E, Thaler, J, Keil, F, Gruenberger, B, Hejna, M, Eisterer, W, Fridrik, MA, Ulmer, H, Trommet, V, Huemer, F, Weiss, L, Greil, R. Anticancer Res. 2017, 37(10):5553-5558.
The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling.
Seeber, A, Gastl, G, Eisterer, W, Gampenrieder, SP, Gerger, A, Kieler, M, Pichler, M, Prager, GW, Untergasser, G, Weltermann, A, Greil, R. MEMO-MAG EUR MED ONC. 2017, 10(4): 255-258.
Synergistic effects of dendritic cell targeting and laser-microporation on enhancing epicutaneous skin vaccination efficacy.
Machado, Y, Duinkerken, S, Hoepflinger, V, Mayr, M, Korotchenko, E, Kurtaj, A, Pablos, I, Steiner, M, Stoecklinger, A, Lübbers, J, Schmid, M, Ritter, U, Scheiblhofer, S, Ablinger, M, Wally, V, Hochmann, S, Raninger, AM, Strunk, D, van Kooyk, Y, Thalhamer, J, Weiss, R. J Control Release. 2017, 266:87-99.
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
nnerthaler, G, Romeder, F, M. J Clin Oncol. 2017, 35(22):2473-2481.
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer, W, Piringer, G, De Vries, A, Ofner, D, Greil, R, Tschmelitsch, J, Samonigg, H, Solkner, L, Gnant, M, Thaler, J. Anticancer Res. 2017, 37(5):2683-2691.
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Magnes, T, Melchardt, T, Hufnagl, C, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Rinnerthaler, G, Roesch, S, Gaggl, A, Greil, R, Egle, A. Pharmacogenomics J. 2017.
Differences in stem cell processing lead to distinct secretomes secretion - implications for differential results of previous clinical trials of stem cell therapy for myocardial infarction.
Wernly, B, Gonçalves, I, Kiss, A, Paar, V, Mösenlechner, T, Leisch, M, Santer, D, Motloch, L, Klein, KU, Tretter, EV, Kretzschmar, D, Podesser, B, Jung, C, Hoppe, UC, Lichtenauer, M. Biotechnol J. 2017.
Amb a 1 isoforms: unequal siblings with distinct immunological features.
Wolf, M, Twaroch, TE, Huber, S, Reithofer, M, Steiner, M, Aglas, L, Hauser, M, Aloisi, I, Asam, C, Hofer, H, Parigiani, MA, Ebner, C, Bohle, B, Briza, P, Angela, N, Stolz, F, Jahn-Schmid, B, Wallner, M, Ferreira, F. Allergy. 2017.
The Human NADPH Oxidase, Nox4, Regulates Cytoskeletal Organization in Two Cancer Cell Lines, HepG2 and SH-SY5Y.
Auer, S, Rinnerthaler, M, Bischof, J, Streubel, MK, Breitenbach-Koller, H, Geisberger, R, Aigner, E, Cadamuro, J, Richter, K, Sopjani, M, Haschke-Becher, E, Felder, TK, Breitenbach, M. Front Oncol. 2017, 7:111.
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer, W, Piringer, G, De Vries, A, Ofner, D, Greil, R, Tschmelitsch, J, Samonigg, H, Solkner, L, Gnant, M, Thaler, J. Anticancer Res. 2017, 37(5):2683-2691.
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
Pleyer, L, Dohner, H, Dombret, H, Seymour, JF, Schuh, AC, Beach, CL, Swern, AS, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Spandl, SM, Zebisch, A, Pichler, A, Pfeilstocker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R. INT J MOL SCI. 2017, 18(2): 415.
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation.
Wolff, F, Leisch, M, Greil, R, Risch, A, Pleyer, L. Cell Commun Signal. 2017, 15(1):13.
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
Greil, R, ObrtlГkovГЎ, P, Smolej, L, KozГЎk, T, Steurer, M, Andel, J, Burgstaller, S, MikuЕЎkovГЎ, E, Gercheva, L, NГ¶sslinger, T, PapajГk, T, LadickГЎ, M, Girschikofsky, M, HrubiЕЎko, M, JГ¤ger, U, Fridrik, M, Pecherstorfer, M, KrГЎlikovГЎ, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, FlochovГЎ, E, PalГЎЕЎthy, S, StehlГkovГЎ, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A. Lancet Haematol. 2016, 3(7): e317-e329.
Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.
Shatirishvili, M, Burk, AS, Franz, CM, Pace, G, Kastilan, T, Breuhahn, K, Hinterseer, E, Dierich, A, Bakiri, L, Wagner, EF, Ponta, H, Hartmann, TN, Tanaka, M, Orian-Rousseau, V. Cell Death Dis. 2016, 7(11):e2461.
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide?+?dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Elevated Toll-Like Receptor-Induced CXCL8 Secretion in Human Blood Basophils from Allergic Donors Is Independent of Toll-Like Receptor Expression Levels.
Steiner, M, Hawranek, T, Schneider, M, Ferreira, F, Horejs-Hoeck, J, Harrer, A, Himly, M. PLOS ONE. 2016, 11(2): e0149275.
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Zebisch, A, Pichler, A, Pfeilstöcker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Geissler, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R. J HEMATOL ONCOL. 2016, 9: 39.
Epidermal-specific deletion of CD44 reveals a function in keratinocytes in response to mechanical stress.
Shatirishvili, M, Burk, AS, Franz, CM, Pace, G, Kastilan, T, Breuhahn, K, Hinterseer, E, Dierich, A, Bakiri, L, Wagner, EF, Ponta, H, Hartmann, TN, Tanaka, M, Orian-Rousseau, V. Cell Death Dis. 2016, 7(11):e2461.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Greil, R, ObrtlГkovГЎ, P, Smolej, L, KozГЎk, T, Steurer, M, Andel, J, Burgstaller, S, MikuЕЎkovГЎ, E, Gercheva, L, NГ¶sslinger, T, PapajГk, T, LadickГЎ, M, Girschikofsky, M, HrubiЕЎko, M, JГ¤ger, U, Fridrik, M, Pecherstorfer, M, KrГЎlikovГЎ, E, Burcoveanu, C, Spasov, E, Petzer, A, Mihaylov, G, Raynov, J, Oexle, H, Zabernigg, A, FlochovГЎ, E, PalГЎЕЎthy, S, StehlГkovГЎ, O, Doubek, M, Altenhofer, P, Pleyer, L, Melchardt, T, Klingler, A, Mayer, J, Egle, A. Lancet Haematol. 2016, 3(7):e317-e329.
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Kollek, M, MГјller, A, Egle, A, Erlacher, M. FEBS J. 2016, 283(15):2779-2810.
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer, L, Burgstaller, S, Stauder, R, Girschikofsky, M, Sill, H, Schlick, K, Thaler, J, Halter, B, Machherndl-Spandl, S, Zebisch, A, Pichler, A, Pfeilstocker, M, Autzinger, EM, Lang, A, Geissler, K, Voskova, D, Geissler, D, Sperr, WR, Hojas, S, Rogulj, IM, Andel, J, Greil, R. J Hematol Oncol. 2016, 9:39.
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells.
Zaborsky, N, Gassner, FJ, Asslaber, D, Reinthaler, P, Denk, U, Flenady, S, Hofbauer, JP, Danner, B, Rebhandl, S, Harrer, A, Geisberger, R, Greil, R, Egle, A. Oncotarget. 2016.
Standardization of allergen products: 2. Detailed characterization of GMP-produced recombinant Phl p 5.0109 as European Pharmacopoeia reference standard.
Himly, M, Nandy, A, Kahlert, H, Thilker, M, Steiner, M, Briza, P, Neubauer, A, Klysner, S, van Ree, R, Buchheit, KH, Vieths, S, Ferreira, F,f. Allergy. 2016, 71(4):49-504.
Elevated Toll-Like Receptor-Induced CXCL8 Secretion in Human Blood Basophils from Allergic Donors Is Independent of Toll-Like Receptor Expression Levels.
Steiner, M, Hawranek, T, Schneider, M, Ferreira, F, Horejs-Hoeck, J, Harrer, A, Himly, M. PLoS One. 2016, 11(2):e0149275.
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik, MA, Jaeger, U, Petzer, A, Willenbacher, W, Keil, F, Lang, A, Andel, J, Burgstaller, S, Krieger, O, Oberaigner, W, Sihorsch, K, Greil, R. Eur J Cancer. 2016, 58:112-121.
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
"Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, KA, Liptrot, S, O""Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P." Leukemia. 2016, 30(4):929-936.
Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR).
DPYD Genotyping to Predict Adverse Events Following Treatment With Flourouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.
Boige, V, Vincent, M, Alexandre, P, Tejpar, S, Landolfi, S, Le Malicot, K, Greil, R, Cuyle, PJ, Yilmaz, M, Faroux, R, Matzdorff, A, Salazar, R, Lepage, C, Taieb, J, Laurent-Puig, P. JAMA Oncol. 2016, xx.
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Ludwig, H, Greil, R, Masszi, T, Spicka, I, Shpilberg, O, Hajek, R, Dmoszynska, A, Paiva, B, Vidriales, MB, Esteves, G, Stoppa, AM, Robinson, D, Chaturvedi, S, Ataman, O, Enny, C, Feng, H, van de Velde, H, Viterbo, L. Br J Haematol. 2015, 171(3): 3-54.
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Fitzal, F, Filipits, M, Rudas, M, Greil, R, Dietze, O, Samonigg, H, Lax, S, Herz, W, Dubsky, P, Bartsch, R, Kronenwett, R, Gnant, M. Br J Cancer. 2015, 112(8): 1405-1410.
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.
Leierer, G, Grabmeier-Pfistershammer, K, Steuer, A, Geit, M, Sarcletti, M, Haas, B, Kanatschnig, M, Rappold, M, Zangerle, R, Ledergerber, B, Taylor, N. PLOS ONE. 2015, 10(11).
Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
Nachbaur, D, Angelova, O, Orth-Holler, D, Ditlbacher, A, Lackner, M, Auberger, J, Lass-Florl, C. EUR J HAEMATOL. 2015, 94(3): 258-264.
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
Tiede, A, Klamroth, R, Scharf, RE, Trappe, RU, Holstein, K, Huth-Kühne, A, Gottstein, S, Geisen, U, Schenk, J, Scholz, U, Schilling, K, Neumeister, P, Miesbach, W, Manner, D, Greil, R, von Auer, C, Krause, M, Leimkühler, K, Kalus, U, Blumtritt, J, Werwitzke, S, Budde, E, Koch, A, Knöbl, P. Blood. 2015, 125(7): 1091-1097.
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians.
Stadlmayr, A, Aigner, E, Huber-Schönauer, U, Niederseer, D, Zwerina, J, Husar-Memmer, E, Hohla, F, Schett, G, Patsch, W, Datz, C. Acta Diabetol. 2015, 52(1):39-46.
IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer-Results of a case series after 5-year follow-up.
Fastner, G, Reitsamer, R, Ziegler, I, Zehentmayr, F, Fussl, C, Kopp, P, Peintinger, F, Greil, R, Fischer, T, Deutschmann, H, Sedlmayer, F. Int J Cancer. 2015, 136(5): 1193-1201.
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Knauer, M, Moik, M, Jakesz, R, Seifert, M, Taucher, S, Bjelic-Radisic, V, Balic, M, Eidtmann, H, Eiermann, W, Steger, G, Kwasny, W, Dubsky, P, Selim, U, Fitzal, F, Hochreiner, G, Wette, V, Sevelda, P, Ploner, F, Bartsch, R, Fesl, C, Greil, R. Ann Oncol. 2015, 26(2):313-320.
"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin""s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial."
Behringer, K, Goergen, H, Hitz, F, Zijlstra, JM, Greil, R, Markova, J, Sasse, S, Fuchs, M, Topp, MS, Soekler, M, Mathas, S, Meissner, J, Wilhelm, M, Koch, P, Lindemann, H, Schalk, E, Semrau, R, Kriz, J, Vieler, T, Bentz, M, Lange, E, Mahlberg, R, Hassler, A, Vogelhuber, M, Hahn, D, Mezger, J, Krause, SW, Skoetz, N, Böll, B, von Tresckow, B, Diehl, V, Hallek, M, Borchmann, P, Stein, H, Eich, H, Engert, A. Lancet. 2015, 385(9976):1418-1427.
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Gnant, M, Sestak, I, Filipits, M, Dowsett, M, Balic, M, Lopez-Knowles, E, Greil, R, Dubsky, P, Stoeger, H, Rudas, M, Jakesz, R, Ferree, S, Cowens, JW, Nielsen, T, Schaper, C, Fesl, C, Cuzick, J. ANN ONCOL. 2015, 26(8): 1685-1691.
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, Greil R, Geisberger R. Haematologica. 2014 May,99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21.
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Knauer, M, Moik, M, Jakesz, R, Seifert, M, Taucher, S, Bjelic-Radisic, V, Balic, M, Eidtmann, H, Eiermann, W, Steger, G, Kwasny, W, Dubsky, P, Selim, U, Fitzal, F, Hochreiner, G, Wette, V, Sevelda, P, Ploner, F, Bartsch, R, Fesl, C, Greil, R Ann Oncol. 2015 Feb,26(2):313-20. doi: 10.1093/annonc/mdu544
"The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by on-demand"" addition of plerixafor to granulocyte-colony-stimulating factor."""
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M Ann Oncol. 2014 Feb,25(2):366-71. doi: 10.1093/annonc/mdt508. Epub 2013 Dec 16.
C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients.
Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Pichler M. Br J Cancer. 2014 Jul 8,111(1):55-60. doi: 10.1038/bjc.2014.277. Epub 2014 May 29.
Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
Human immunodeficiency virus type 2 infections in Austria.
Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, Greil R, Oberkofler H, Eberle J. Wien Klin Wochenschr. 2014 Apr,126(7-8):212-6. doi: 10.1007/s00508-013-0493-1. Epub 2014 Jan 18.
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, Egle A, Greil R. Ann Hematol. 2014 Mar,93(3):459-62. doi: 10.1007/s00277-014-2009-0. Epub 2014 Jan 18.
Pleural decortication of a marginal zone lymphoma.
Melchardt T, Weiss L, Namberger K, Pretsch I, Hutter J, Rettenbacher L, Neureiter D, Troch M, Greil R, Egle A. Ann Hematol. 2014 Jul,93(7):1253-4. doi: 10.1007/s00277-013-1960-5. Epub 2013 Nov 22.
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie. Lancet. 2015 Apr 11,385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22.
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.
Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, Greil R,von Auer C, Krause M, Leimkühler K, Kalus U, Blumtritt J, Werwitzke S, Budde E, Koch A, Knöbl P. Blood. 2015 Feb 12,125(7):1091-7. doi: 10.1182/blood-2014-07-587089. Epub 2014 Dec 18.
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.
Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, Autzinger EM, Heintel D, Greil R, Poenisch W, MГјldГјr E, Zojer N. Haematologica. 2015 Mar,100(3):385-91. doi: 10.3324/haematol.2014.115204. Epub 2014 Nov 14.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, et al. N Engl J Med. 2014 Sep 4,371(10):906-17. doi: 10.1056/NEJMoa1402551.
A randomized, open-label multicentre phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC Br J Haematol. 2014 Nov,167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R. Lung Cancer. 2014 Sep,85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.
Oxaliplatin, fluorouracil and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label randomised phase 3 trial.
Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C Lancet Oncol. 2014 Jul,15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Lancet. 2014 Jun 21,383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, et al. Clin Cancer Res. 2014 Mar 1,20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.
Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.
Taylor N, Haschke-Becher E, Greil R, Strasser M, Oberkofler H. Antivir Ther. 2014,19(5):449-54. doi: 10.3851/IMP2723. Epub 2014 Jan 16.
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, et al. Ann Oncol. 2014 Feb,25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind phase 3 trial.
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC and UCHL1.
Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N. Mod Pathol. 2014 Jun,27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.
Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G Ann Hematol. 2014 Feb,93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30.
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y J Antimicrob Chemother. 2014 Apr,69(4):1090-7. doi: 10.1093/jac/dkt474. Epub 2013 Nov 27.
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, WeiГџmann A, Adam Z. Blood. 2014 Feb 13,123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13.
A PHASE II STUDY OF RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT LYMPHOMA)
Raderer, M, Kiesewetter, B, Willenbacher, W, Neumeister, P, Fridrik, M, Greil, R HAEMATOLOGICA. 2014, 99: 226-226.
AN INTERNATIONAL, MULTICENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF NEUTROPENIA IN PATIENTS BEING TREATED WITH LENALIDOMIDE plus DEXAMETHASONE FOR RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR-MM)
INTERIM RESULTS FROM A PHASE IIA STUDY OF THE ANTI-CXCL12 SPIEGELMER OLAPTESED PEGOL (NOX-A12) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA
Ludwig, H, Weisel, K, Petrucci, MT, Leleu, X, Cafro, AM, Kropff, M, Greil, R, Zojer, N, Dummler, T, Kruschinski, A, Riecke, K, Foa, R, Yakoub-Agha, I, Engelhardt, M HAEMATOLOGICA. 2014, 99: 115-116.
Schmidt, S, Sill, H, Greil, R, Burgstaller, S, Sliwa, T, Petzer, A, Lang, A, Weltermann, A, Voskova, D, Mitterer, M, Valent, P, Eberhard, N, Walder, A, Geissler, K, Andel, J, Hausler, C, Ludescher, C, Oexle, H, Korger, M, Schnallinger, M, Schreieck, S, Krippl, P, Pober, M, Woell, E, Geissler, D, Rochau, U, Siebert, U, Thaler, J, Gastl, G ONCOL RES TREAT. 2014, 37: 57-58.
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck
Keil, F, Selzer, E, Berghold, A, Reinisch, S, de Vries, A, Greil, R, Bachtiary, B, Tinchon, C, Anderhuber, W, Burian, M, Kasparek, AK, Elsasser, W, Kainz, H, Riedl, R, Kapp, K, Kopp, M, Kornek, G ONCOL RES TREAT. 2014, 37: 273-273. Ebenfalls in Pubmed gefunden: Eur J Cancer. 2013 Jan,49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first disease progression (PD) in patients with metastatic colorectal cancer (mCRC) previously treated with BEV-based therapy: Outcomes according to KRAS status and first-line CT backbone in the ML18147 study.
Kubicka, S, Greil, R, Andre, T, Bennouna, J, Sastre, J, Van Cutsem, E, Von Moos, R, Osterlund, PJ, Hegde, P, Sersch, MA, Osborne, S, Hermann, F, Arnold, D J CLIN ONCOL. 2014, 32(3):
Hartmann TN Blood. 2014 Jun 5,123(23):3533-4. doi: 10.1182/blood-2014-04-565358. Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. [Blood. 2014]
Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results
Vornamen sind ausgeschrieben-Г¤ndern? Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A. Fridrik, Josef Thaler, Alois Lang, Richard Greil, Blood (ASH Annual Meeting Abstracts). 2013. #4164:
CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility.
Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, Hauser-Kronberger C, Neureiter D, Kerschbaum H, Naor D, Alon R, Greil R, Hartmann TN. Cancer Res. 2013 Jan 15,73(2):561-70. doi: 10.1158/0008-5472.CAN-12-2749. Epub 2012 Nov 1.
Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.
Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H. PLoS One. 2013 Aug 30,8(8):e74024. doi: 10.1371/journal.pone.0074024. eCollection 2013.
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.
Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, Greil R. Ann Hematol. 2013 Jul,92(7):1001-2. doi: 10.1007/s00277-012-1659-z. Epub 2012 Dec 28.
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R. Br J Cancer. 2013 Aug 6,109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18.
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
Baselga J, GГіmez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, PГЄgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, MelezГnkovГЎ H, Awada A. J Clin Oncol. 2013 Jul 10,31(20):2586-92. doi: 10.1200/JCO.2012.46.2408. Epub 2013 Jun 3.
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V. J Clin Oncol. 2013 May 10,31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8.
Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M Br J Cancer. 2013 Apr 16,108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19.
ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. J Clin Oncol. 2013 Apr 20,31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label non-inferiority phase 3 TURANDOT trial.
Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C Lancet Oncol. 2013 Feb,14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10.
A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.
Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN. Clin Cancer Res. 2013 Jan 15,19(2):500-7. doi: 10.1158/1078-0432.CCR-12-2153. Epub 2012 Dec 4.
Randomized phase II study of bortezomib, thalidomide and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. J Clin Oncol. 2013 Jan 10,31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22.
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M Ann Oncol. 2013 Mar,24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3.
Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, MГјllauer L, Greil R, Raderer M. Haematologica. 2013 Feb,98(2):264-8. doi: 10.3324/haematol.2012.072587. Epub 2012 Sep 14.
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, Greil R, Bachtiary B, Tinchon C, Anderhuber W, Burian M, Kasparek AK, Elsäßer W, Kainz H, Riedl R, Kopp M, Kornek G. Eur J Cancer. 2013 Jan,49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.
Two patients diagnosed with coexisting hematologic and oncologic BRAF V600E mutated malignancies. Which entity is really carrying the BRAF (V600E) mutation?
Schlick, K, Troch, M, Placher-Sorko, G, Faber, V, Neureiter, D, Greil, R, Hopfinger, G ONKOLOGIE. 2013, 36: 168-169.
Lapatinib plus Caelyx in patients with advanced or metastatic Her 2 positive breast cancer following failure of Trastuzumab therapy - A Phase II study of the Arbeitsgemeinschaft Medikamentose Tumortherapie
Pircher, M, Mlineritsch, B, Fridrik, M, Dittrich, C, Lang, A, Petru, E, Weltermann, A, Thaler, J, Hufnagl, C, Gampenrieder, SP, Ressler, S, Rinnerthaler, G, Ulmer, H, Greil, R ONKOLOGIE. 2013, 36: 159-159.
Schmidt, S, Burgstaller, S, Linkesch, W, Greil, R, Schlogl, E, Fridrik, M, Krieger, O, Petzer, A, Lang, A, Mitterer, M, Valent, P, Walder, A, Sliwa, T, Keil, F, Korger, M, Hausler, C, Woll, E, Oexle, H, Schnallinger, M, Pober, M, Rochau, U, Siebert, U, Thaler, J, Gastl, G ONKOLOGIE. 2013, 36: 63-63.
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.
Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V. Blood. 2013 Nov 7,122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.
p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa.
Valente LJ, Gray DH, Michalak EM, Pinon-Hofbauer J, Egle A, Scott CL, Janic A, Strasser A. Cell Rep. 2013 May 30,3(5):1339-45. doi: 10.1016/j.celrep.2013.04.012. Epub 2013 May 9.
Protein Kinase C-?-Dependent Activation of NF-?B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo.
Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I. Cancer Cell. 2013 Jan 14,23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.
Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.
Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M, Schlederer M, Steurer M, Kenner L, Greil R. Leukemia. 2012 Dec,26(12):2508-16. doi: 10.1038/leu.2012.147. Epub 2012 Jun 1.
Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient
Thomas Melchardt, Lukas Weiss, Clemens Hufnagl, Daniel Neureiter, Ralf Kemmerling, Patrick Morre, Ann Boekstegers, Georg Hopfinger, Richard Greil, Alexander Egle, Blood (ASH Annual Meeting Abstracts) 2012. 2012. #1613:
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Gisslinger, H, Kralovics, R, Gisslinger, B, Lechner, D, Buxhofer-Ausch, V, Strecker, K, Gastl, G, Willenbacher, E, Greil, R, Egle, A, Melchardt, T, Burgstaller, S, Schloegl, E, Tarmann, FJ, Zoerer, M, Klade, C, Zahriychuk, O, Thaler, J BLOOD. 2012, 120(21):
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
Thaler J, Karthaus M, Mineur L, Greil R, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH. BMC Cancer. 2012 Sep 29,12:438. doi: 10.1186/1471-2407-12-438.
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group.
Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, Greil R, Porschen R, Arnold D, Schmiegel W, Tannapfel A. BMC Cancer. 2012 Aug 9,12:349. doi: 10.1186/1471-2407-12-349.
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I, Inbar MJ, KahГЎn Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T, Zielinski C. Eur J Cancer. 2012 Nov,48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26.
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R Haematologica. 2012 Sep,97(9):1431-8. Epub 2012 Apr 17.
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled multicenter multinational double-blinded phase II trial.
Schimanski CC, Möhler M, Schön M, van Cutsem E, Greil R, Bechstein WO, Hegewisch-Becker S, von Wichert G, Vöhringer M, Heike M, Heinemann V, Peeters M, Kanzler S, Kasper S, Overkamp F, Schröder J, Seehofer D, Kullmann F, Linz B, Schmidtmann I, Smith-Machnow V, Gockel I, et al. BMC Cancer. 2012 Apr 11,12:144. doi: 10.1186/1471-2407-12-144.
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label phase 3 non-inferiority trial.
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, et al. Lancet. 2012 May 12,379(9828):1791-9. doi: 10.1016/S0140-6736(11)61940-5. Epub 2012 Apr 4.
The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
Aapro M, Molassiotis A, Dicato M, PelГЎez I, RodrГguez-Lescure ГЃ, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F Ann Oncol. 2012 Aug,23(8):1986-92. Epub 2012 Mar 6.
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].
Pabinger I, Gastl G, Steurer M, Sormann S, Fillitz M, Friedl J, Geissler D, Geissler K, Greil R, Knöbl P, Kozek-Langenecker S, Krippl P, Kyrle P, Lang A, Linkesch W, Ludwig H, Müller M, Panzer S, Pittermann E, Thaler J, Weltermann A. Wien Klin Wochenschr. 2012 Feb,124(3-4):111-23. doi: 10.1007/s00508-012-0123-3. Epub 2012 Mar 3.
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. J Clin Oncol. 2012 Mar 20,30(9):921-9. doi: 10.1200/JCO.2011.35.7376. Epub 2012 Feb 13.
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y, Marks S J Antimicrob Chemother. 2012 Mar,67(3):685-90. doi: 10.1093/jac/dkr533. Epub 2011 Dec 29.
Prognostic value of number of removed lymph nodes, number of involved lymph nodes and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M. Ann Surg Oncol. 2012 Jun,19(6):1808-17. doi: 10.1245/s10434-011-2189-y. Epub 2011 Dec 30.
Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
Jöhrer K, Obkircher M, Neureiter D, Parteli J, Zelle-Rieser C, Maizner E, Kern J, Hermann M, Hamacher F, Merkel O, Wacht N, Zidorn C, Scheideler M, Greil R. J Mol Med (Berl). 2012 Jun,90(6):681-93. doi: 10.1007/s00109-011-0848-x. Epub 2011 Dec 29.
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
GrГјnwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I Eur J Cancer. 2012 Feb,48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.
Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).
Arnold, D, Andre, T, Bennouna, J, Sastre, J, Osterlund, PJ, Greil, R, Van Cutsem, E, Von Moos, R, Reyes-Rivera, I, Bendahmane, B, Kubicka, S J CLIN ONCOL. 2012, 30(18):
BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)
Gianni, L, Chan, A, Mansutti, M, Pivot, X, Greil, R, Provencher, L, Prot, S, Moore, N, Scherer, SJ, Pallaud, C ANN ONCOL. 2012, 23: 531-532.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)
Greil, R, Arnold, D, Hegewisch-Becker, S, Freier, W, Steffens, CC, Bertram, M, Schlichting, C, Andel, J, Taylor, M, Makrutzki, M, Kubicka, S ONKOLOGIE. 2012, 35: 254-254.
IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
Ludwig, H, Kasparu, H, Leitgeb, C, Greil, R, Rauch, E, Linkesch, W, Zojer, N, Pour, L, Fillitz, M, Adam, Z ANN ONCOL. 2012, 23: 348-349.
RITUXIMAB PLUS SUBCUTANEOUS CLADRIBINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED TISSUE (MALT-LYMPHOMA): A PHASE II STUDY BY THE AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE)
Troch, M, Kiesewetter, B, Willenbacher, W, Willenbacher, E, Zebisch, A, Linkesch, W, Fridrik, MA, Mullauer, L, Greil, R, Raderer, M ANN ONCOL. 2012, 23: 352-352.
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
dxxxAmore, F, Leppa, S, da Silva, MC, Relander, T, Brown, PD, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, van Gelder, M, Doorduijn, JK, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, UM, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nosslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, I, Salek, D, Jyrkkio, S, Prochazka, V, Zijlstra, J, Bohmer, L, Greil, R, Stevens, W, Fijnheer, R, Kooy, MV, Grube, M, Hopfinger, G, Van den Neste, E, Jantunen, E, Trumper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Toldbod, H BLOOD. 2012, 120(21):
A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results
Egle, A, Steurer, M, Gassner, F, Geisberger, R, Melchardt, T, Weiss, L, Fridrik, MA, Thaler, J, Lang, A, Greil, R BLOOD. 2011, 118(21): 135-136.
Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study
Tumor load reduction and prolongation of overall-survival by actinomycin D in a murine model of high-risk chronic lymphocytic leukemia
Wacht, N, Sifft, E, Melchardt, T, Hamacher, F, Denk, U, Pinon-Hofbauer, J, Egle, A, Kocher, T, Steurer, M, Greil, R, Merkel, O ONKOLOGIE. 2011, 34: 141-141.
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Wöll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Dlaska M, Obrist P, Thaler J. Anticancer Res. 2011 Dec,31(12):4439-43.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Lancet. 2011 Nov 12,378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M Clin Cancer Res. 2011 Dec 15,17(24):7828-34. doi: 10.1158/1078-0432.CCR-11-1846. Epub 2011 Oct 13.
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. J Clin Oncol. 2011 Nov 10,29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Epub 2011 Oct 11.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, et al. PLoS One. 2011,6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Lancet. 2011 Aug 27,378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.
Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools.
Merkel O, Hamacher F, Sifft E, Kenner L, Greil R Mol Cancer Ther. 2011 Jul,10(7):1127-36. doi: 10.1158/1535-7163.MCT-11-0042. Epub 2011 Jun 28. Review.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R Lancet Oncol. 2011 Jul,12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M, Mlineritsch B, Ressler S, Moik M, Kappacher A, Rosenlechner S, Greil R. Oncology. 2011,80(1-2):34-41. doi: 10.1159/000328086. Epub 2011 May 23.
Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.
Greil R, BorГ…ВЎtnar S, PetrГЎkovГЎ K, Marcou Y, Pikiel J, Wojtukiewicz MZ, Koza I, Steger GG, Linn M, Das Gupta A, Cwiertka K. Onkologie. 2011,34(5):233-8. doi: 10.1159/000327710. Epub 2011 Apr 26.
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.
Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R. Breast J. 2011 May-Jun,17(3):230-8. doi: 10.1111/j.1524-4741.2011.01073.x. Epub 2011 Mar 31.
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G Ann Hematol. 2011 Sep,90(9):1083-91. doi: 10.1007/s00277-011-1192-5. Epub 2011 Feb 25.
Preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with newly diagnosed primary operable cT₃NxM0 low rectal cancer: a phase II study.
Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J Strahlenther Onkol. 2011 Feb,187(2):100-7. doi: 10.1007/s00066-010-2182-6. Epub 2011 Jan 21.
Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N, Hartog CM, Bassan R, Derigs HG, Dombret H, Greil R, Hernández-Rivas JM, Huguet F, Intermesoli T, Jourdan E, Junghanss C, Leimer L, Moreno MJ, Reichle A, Ribera J, Schmid M, Serve H, Stelljes M, Stuhlmann R, Hoelzer D Haematologica. 2011 Feb,96(2):238-44. doi: 10.3324/haematol.2010.028092. Epub 2010 Oct 15.
62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer
Lower incidence of BCR-ABL mutations and improved molecular response kinetics in newly diagnosed CML patients treated with nilotinib compared with imatinib
Muller, MC, le Coutre, P, Gattermann, N, Scheid, C, Al-Ali, HK, Ottmann, OG, Duyster, J, Blumenstengel, K, Brummendorf, TH, Greil, R, Chalandon, Y, Valent, P, Stegelmann, F, Kneba, M, Schafhausen, P, Saussele, S, Frank, O, Larson, RA, Saglio, G, Hochhaus, A, Lange, T ONKOLOGIE. 2011, 34: 266-266.
DOSE-ESCALATION WITH BEACOPP ESCALATED IS SUPERIOR TO ABVD IN THE COMBINED-MODALITY TREATMENT OF EARLY UNFAVORABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL
Borchmann, P, Diehl, V, Plutschow, A, Von Tresckow, B, Markova, J, Hitz, F, Kra, Z, Greil, R, Topp, MS, Villalobos, M, Zijlstra, JM, Sokler, M, Fuchs, M, Engert, A ANN ONCOL. 2011, 22: 180-180.
Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28 June 2011.
Merkel O, Kenner L, Turner SD. Leukemia. Dec,25(12):1795-6. doi: 10.1038/leu.2011.295.
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients.
Perkhofer S, Lass-Flörl C, Hell M, Russ G, Krause R, Hönigl M, Geltner C, Auberger J, Gastl G, Mitterbauer M, Willinger B, Knöbl P, Resch G, Waldner R, Makrai A, Hartmann G, Girschikofsky M, Greil R. Int J Antimicrob Agents. 2010 Dec,36(6):531-6. doi: 10.1016/j.ijantimicag.2010.08.010. Epub 2010 Oct 13.
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, Greil R. Blood. 2010 May 27,115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20.
Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study
Egle, A, Weiss, L, Melchardt, T, Gunsilius, E, Petzer, AL, Fridrik, M, Lang, A, Krieger, O, Thaler, J, Greil, R BLOOD. 2010, 116(21): 593-594.
Deletion of Puma and p21(Waf1) In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence
Hofbauer, JP, Holler, C, Denk, U, Asslaber, D, Fastner, G, Labi, V, Villunger, A, Greil, R, Egle, A BLOOD. 2010, 116(21): 45-46.
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. J Natl Cancer Inst Monogr. 2010,2010(41):162-77. doi: 10.1093/jncimonographs/lgq039.
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R. Br J Cancer. 2010 Oct 12,103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28.
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H, Adam Z, Hajek R, Greil R, TГіthovГЎ E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. J Clin Oncol. 2010 Oct 20,28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7.
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, et al. N Engl J Med. 2010 Aug 12,363(7):640-52. doi: 10.1056/NEJMoa1000067.
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L. Proc Natl Acad Sci U S A. 2010 Sep 14,107(37):16228-33. doi: 10.1073/pnas.1009719107. Epub 2010 Aug 30.
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. J Clin Oncol. 2010 Sep 20,28(27):4199-206. doi: 10.1200/JCO.2010.29.8018. Epub 2010 Aug 16.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM N Engl J Med. 2010 Jun 17,362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M, Erdel M, Tinhofer I, Brychtova Y, Panovska A, Doubek M, Eigenberger K, Fonatsch C, Hopfinger G, MГјhlberger H, Zabernigg A, Falkner F, Gastl G, Mayer J, Greil R Ann Oncol. 2010 Dec,21(12):2410-9. doi: 10.1093/annonc/mdq236. Epub 2010 May 13.
PLZF/ZBTB16, a glucocorticoid response gene in acute lymphoblastic leukemia interferes with glucocorticoid-induced apoptosis.
Wasim M, Carlet M, Mansha M, Greil R, Ploner C, Trockenbacher A, Rainer J, Kofler R. J Steroid Biochem Mol Biol. 2010 Jun,120(4-5):218-27. doi: 10.1016/j.jsbmb.2010.04.019. Epub 2010 May 6.
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R. Ann Hematol. 2010 Mar,89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20.
Melchardt T, Weiss L, Pleyer L, Neureiter D, Faber V, Greil R. In Greil R., Pleyer L., Neureiter D., Faber V. (Editors) , Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Wien New York: Springer (2010) , Springer, 2010. (ISBN 978-3-211-79891-1)
Pleyer, L, Kappacher, A, Rosenlechner, S, Greil, R, In: Braumann, KM, Stiller, N (Ed.) editors(s). Bewegungstherapie bei internistischen Erkrankungen.. p. 223-240.
ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12
Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Poestlberger, S, Steger, GG, Jakesz, R, Singer, CF, Eidtmann, H, Greil, R ANN ONCOL. 2010, 21: 79-79.
Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)
Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Rudas, M, Marth, C, Stoeger, H, Singer, CF, Gnant, M EJC SUPPL. 2010, 8(3): 60-60.
Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
Engert, A, Borchmann, P, Pluetschow, A, von Tresckow, B, Markova, J, Hitz, F, Kral, Z, Greil, R, Topp, MS, Villalobos, M, Zijlstra, JM, Soekler, M, Stein, H, Eich, HT, Mueller, RP, Fuchs, M, Diehl, V BLOOD. 2010, 116(21): 336-336.
Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-Study NHL-14)
Fridrik, M, Petzer, AL, Keil, F, Willenbacher, W, Jager, U, Lang, A, Andel, J, Krieger, O, Oberaigner, W, Greil, R BLOOD. 2010, 116(21): 736-737.
Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow.
Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, Binsky I, Vallon-Eberhard A, Sapoznikov A, Burger M, Shachar I, Haran M, Honczarenko M, Greil R, Alon R. Cancer Res. 2009 Apr 1,69(7):3121-30. doi: 10.1158/0008-5472.CAN-08-4136. Epub 2009 Mar 17.
PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.
Holler C, PiГ±Гіn JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A. Blood. 2009 Mar 19,113(12):2791-4. doi: 10.1182/blood-2008-06-160713. Epub 2009 Jan 23.
The REVLIRIT CLL5 AGMT Study - a Phase I/II Trial Combining Fludarabine/Rituximab with Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL): Results of a Planned Interim Analysis
Egle, A, Steurer, M, Melchardt, T, Stoll, M, Greil, R BLOOD. 2009, 114(22): 1341-1342.
FINAL RESULTS OF ORAL FLUDARABINE WITH CONCOMITANT SUBCUTANEOUS ALEMTUZUMAB IN RELAPSED/REFRACTORY B-CHRONIC LYMPHOCYTIC LEUKAEMIA (B-CLL): THE FLUSALEM STUDY
Egle, A, Melchardt, T, Pleyer, L, Tinhofer, I, Lang, A, Keil, F, Thaler, J, Gunsilius, E, Fridrik, M, Greil, R HAEMATOL-HEMATOL J. 2009, 94: 140-140.
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF Clin Cancer Res. 2009 Sep 15,15(18):5888-94. doi: 10.1158/1078-0432.CCR-09-0728. Epub 2009 Sep 1.
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. J Clin Oncol. 2009 Jun 1,27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.
Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study.
Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B. Eur J Surg Oncol. 2009 Oct,35(10):1048-54. doi: 10.1016/j.ejso.2009.01.014. Epub 2009 Feb 27.
Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease.
Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R. J Immunother. 2009 Apr,32(3):302-9. doi: 10.1097/CJI.0b013e318197b5e4.
Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P, Russ G, Rass C, Greil R Onkologie. 2009 Feb,32(1-2):18-24. doi: 10.1159/000180915. Epub 2009 Jan 20.
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma.
Ludwig H, Hajek R, TГіthovГЎ E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A. Blood. 2009 Apr 9,113(15):3435-42. doi: 10.1182/blood-2008-07-169565. Epub 2008 Oct 27.
Hodgkin lymphoma in Tyrol-a population-based study.
Fong D, Steurer M, Greil R, Gunsilius E, Spizzo G, Gastl G, Tzankov A. Ann Hematol. 2009 May,88(5):449-56. doi: 10.1007/s00277-008-0618-1. Epub 2008 Oct 10.
The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells.
Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Greil R, Trejo LE, Kharenko O, Feinmesser M, Yron I, Witz IP. Cancer Lett. 2009 Jan 8,273(1):127-39. doi: 10.1016/j.canlet.2008.07.029. Epub 2008 Sep 7.
A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)
Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Martin, C, Samonigg, H, Kubista, E, Gnant, M EJC SUPPL. 2009, 7(3): 3-3.
NUMBER NEEDED TO TREAT (NNT) AS A MEASURE OF ZOLEDRONIC ACID (ZOL) EFFICACY IN PATIENTS WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (BC) IN THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12 TRIAL
Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, GG, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R ANN ONCOL. 2009, 20: 30-30.
Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
Lang, I, Inbar, M, Steger, G, Greil, R, Zvirbule, Z, Beslija, S, Kahan, Z, Taskova, V, Kaufmann, B, Zielinski, CC EJC SUPPL. 2009, 7(2): 277-278.
Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.
Goetz, M, Ames, M, Gnant, M, Filpits, M, Jakesz, R, Greil, R, Marth, C, Samonigg, H, Suman, V, Safgren, S, Kuffel, M, Weinshilboum, R, Erlander, M, Ma, XJ, Ingle, J CANCER RES. 2009, 69(2): 77S-77S.
The number needed to treat (NNT) as a measure of drug efficacy: the case of zoledronic acid for early hormone-responsive breast cancer in the ABCSG-12 trial
Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, G, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R CANCER RES. 2009, 69(2): 191S-191S.
ADDITION OF ZOLEDRONIC ACID (ZOL) TO ADJUVANT ENDOCRINE THERAPY IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (HREBC): MULTIVARIATE ANALYSES OF THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP 12 (ABCSG-12) TRIAL
Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Poestlberger, S, Menzel, C, Jakesz, R, Kubista, E, Marth, C, Greil, R ANN ONCOL. 2009, 20: 30-30.
Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03
Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer
Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Marth, C, Samonigg, H, Kubista, E, Gnant, M CANCER RES. 2009, 69(24): 564S-564S.
Minimal Residual Disease (MRD) and T/NK Cell Dynamics during Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab in Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): Riskfactor Stratification in the Chairos Study.
Egle, A, Weiss, L, Gassner, F, Russ, G, Pleyer, L, Gunsilius, E, Tinhofer, I, Thaler, J, Petzer, AL, Greil, R BLOOD. 2008, 112(11): 1089-1089.
Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT).
Wöll E, Kühr T, Eisterer W, Gattringer K, Greil R, Zabernigg A, Hilbe W, Thaler J. Anticancer Res. 2008 Sep-Oct,28(5B):2901-5.
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG N Engl J Med. 2008 Aug 28,359(9):906-17. doi: 10.1056/NEJMoa0801479.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R Lancet Oncol. 2008 Sep,9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19.
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I. J Clin Oncol. 2008 May 10,26(14):2252-7. doi: 10.1200/JCO.2007.11.5212.
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M Clin Cancer Res. 2008 Apr 1,14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M Clin Cancer Res. 2008 Mar 15,14(6):1767-74. doi: 10.1158/1078-0432.CCR-07-4122.
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, Stöcher M, Prokesch A, Papak C, Scheideler M, Trajanoski Z, Greil R. J Mol Med (Berl). 2008 May,86(5):541-52. doi: 10.1007/s00109-008-0314-6. Epub 2008 Feb 23.
Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R Breast Cancer Res Treat. 2008 Nov,112(1):203-13. Epub 2007 Dec 22.
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M Breast Cancer Res Treat. 2008 Nov,112(2):309-16. Epub 2007 Dec 14.
ZOLEDRONIC ACID (ZOL) IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (ERBC) RECEIVING ADJUVANT ENDOCRINE THERAPY: MULTIVARIATE ANALYSIS OF EFFICACY DATA FROM THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12
Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, GG, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R ANN ONCOL. 2008, 19: 44-44.
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12
Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Poestlberger, S, Menzel, C, Jakesz, R, Kubista, E, Marth, C, Greil, R J CLIN ONCOL. 2008, 26(15):
A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells.
Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M, Alon R. J Leukoc Biol. 2008 Oct,84(4):1130-40. doi: 10.1189/jlb.0208088. Epub 2008 Jul 24.
Planned first efficacy and safety analysis of de-intensified induction with fludarabine, cyclophosphamide plus rituximab (FCR) followed by fludarabine plus rituximab (FR) and remission maintenance therapy with rituximab in previously untreated B-chronic lymphocytic leukemia (B-CLL): The chairos study
Egle, A, Weiss, L, Russ, G, Thoedtmann, R, Pleyer, L, Gastl, G, Thaler, J, Petzer, A, Tinhofer, I, Greil, R BLOOD. 2007, 110(11): 609A-609A.
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, RГјcklinger E, Samonigg H J Natl Cancer Inst. 2007 Dec 19,99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6,100(3):226.
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ J Clin Oncol. 2007 Sep 20,25(27):4217-23. Epub 2007 Jun 4.
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R J Clin Oncol. 2007 May 20,25(15):2012-8.
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].
Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S. Wien Klin Wochenschr. 2007,119(7-8):259-66.
Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R. Breast Cancer Res Treat. 2007 Nov,106(1):105-12. Epub 2007 Feb 13.
A new sesquiterpene lactone sulfate from Reichardia gaditana (Asteraceae)
Zidorn, C, Ellmerer, EP, Heller, W, Johrer, K, Frommberger, M, Greil, R, Guggenberger, M, Ongania, KH, Stuppner, H Z NATURFORSCH B. 2007, 62(1): 132-134.
Therapy of antibody-mediated factor VIII deficiency by immunosuppressive therapy containing cyclophosphamide, dexamethasone and rituximab: A case report
Thoedtmann, R, Rosenlechner, S, Unger, J, Patsch, W, Greil, R HAEMATOL-HEMATOL J. 2007, 92: 546-546.
Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation.
Mayr JA, Merkel O, Kohlwein SD, Gebhardt BR, Böhles H, Fötschl U, Koch J, Jaksch M, Lochmüller H, Horvath R, Freisinger P, Sperl W. American Journal of Human Genetics. 2007 Mar,80(3):478-84. Epub 2007 Jan 10.
The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
Tinhofer I, Steurer M, Leitinger G, Rumpold H, Egle A, Erdel M, Greil R. Haematologica. 2006 Sep,91(9):1291-3.
Planned first safety and efficacy analysis of oral fludarabine combined with subcutaneous alemtuzumab in 2(nd) line therapy of B-chronic lymphocytic leukaemia (B-CLL): The FLUSALEM study.
Egle, A, Tinhofer, I, Russ, G, Rass, C, Greil, R BLOOD. 2006, 108(11): 336B-336B.
Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R Cancer. 2006 Nov 15,107(10):2408-16.
Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R. Leuk Lymphoma. 2006 Aug,47(8):1683-5.
IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
Falkensammer C, Jöhrer K, Gander H, Ramoner R, Putz T, Rahm A, Greil R, Bartsch G, Thurnher M. Cancer Immunol Immunother. 2006 Oct,55(10):1228-37. Epub 2006 Jan 28.
Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra.
Mian M, Psenak O, Greil R, Fiegl M, Tzankov A. Leuk Lymphoma. 2006 May,47(5):940-3. No abstract available.
Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice.
Keller M, Simbruner G, Gorna A, Urbanek M, Tinhofer I, Griesmaier E, Sarkozy G, Schwendimann L, Gressens P. Pediatric Research. 2006 Apr, 59 (4 Pt 1): 549-53.
Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, TarkovГЎcs G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A. Br J Haematol. 2005 Nov,131(3):329-37.
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J Lancet. 2005 Aug 6-12,366(9484):455-62.
Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.
Eisterer W, Bechter O, Söderberg O, Nilsson K, Terol M, Greil R, Thaler J, Herold M, Finke L, Günthert U, Montserrat E, Stauder R. Leuk Res. 2004 Oct,28(10):1043-51.
Normative data for functional assessment of cancer therapy--general scale and its use for the interpretation of quality of life scores in cancer survivors.
Holzner B, Kemmler G, Cella D, De Paoli C, Meraner V, Kopp M, Greil R, Fleischhacker WW, Sperner-Unterweger B. Acta Oncol. 2004,43(2):153-60.
Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11,18) negative, surgically resected gastrointestinal B cell lymphomas.
Krugmann J, Tzankov A, Dirnhofer S, Fend F, Greil R, Siebert R, Erdel M. J Clin Pathol. 2004 Apr,57(4):360-4.
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, et al. Ann Oncol. 2004 Feb,15(2):276-82.
Treatment of advanced Hodgkinxxxs disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkinxxxs Lymphoma Study Group HD6 trial
Sieber, M, Tesch, H, Pfistner, B, Rueffer, U, Paulus, U, Munker, R, Hermann, R, Doelken, G, Koch, P, Oertel, J, Roller, S, Worst, P, Bischof, H, Glunz, A, Greil, R, von Kalle, K, Schalk, KP, Hasenclever, D, Brosteanu, O, Duehmke, E, Georgii, A, Engert, A, Loeffler, M, Diehl, V ANN ONCOL. 2004, 15(2): 276-282.
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, et al. Leuk Res. 2003 May,27(5):405-11.
The impact of hemoglobin levels on fatigue and quality of life in cancer patients.
Holzner B, Kemmler G, Greil R, Kopp M, Zeimet A, Raderer M, Hejna M, Zöchbauer S, Krajnik G, Huber H, Fleischhacker WW, Sperner-Unterweger B. Ann Oncol. 2002 Jun,13(6):965-73.
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, et al. J Clin Oncol. 2002 Jan 15,20(2):476-84.
Stepping up treatment with Rituxan (R) (rituximab, Mabthera (R)) for CLL patients with advanced stage of disease relapsing after or refractory to conventional chemotherapy.
Greil, R, Steurer, M, Egle, A, Stauder, R, Anether, G, Ulmer, L, Tinhofer, I, Gastl, G BLOOD. 2001, 98(11): 289B-290B.
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Leuk Lymphoma. 2001 Nov-Dec,42(6):1283-8.
Epstein-Barr virus-associated extranodal NK/T-cell lymphoma, nasal type of the hypopharynx in a renal allograft recipient: case report and review of literature.
Quality of life measurement in oncology--a matter of the assessment instrument?
Holzner B, Kemmler G, Sperner-Unterweger B, Kopp M, DГјnser M, Margreiter R, Marschitz I, Nachbaur D, Fleischhacker WW, Greil R. Eur J Cancer. 2001 Dec,37(18):2349-56.
Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone.
DГјhmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, RГјhl U, MГјller RP, Lukas P, Atzinger A, Paulus U, Lathan B, RГјffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, et al. J Clin Oncol. 2001 Jun 1,19(11):2905-14.
Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G, Holzner B, Kopp M, DГјnser M, Margreiter R, Greil R, Sperner-Unterweger B. J Clin Oncol. 1999 Sep,17(9):2932-40.
Synergistic action of protein kinase C theta and calcineurin is sufficient for Fas ligand expression and induction of a crmA-sensitive apoptosis pathway in Jurkat T cells.
Villunger A, Ghaffari-Tabrizi N, Tinhofer I, Krumböck N, Bauer B, Schneider T, Kasibhatla S, Greil R, Baier-Bitterlich G, Uberall F, Green DR, Baier G. Eur J Immunol. 1999 Nov,29(11):3549-61.
Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994.
Greil R, Holzner B, Kemmler G, Kopp M, Buchowski A, Oberaigner W, Fritsch E, Dirnhofer S, Rueffer U, Diehl V, Sperner-Unterweger B. Eur J Cancer. 1999 May,35(5):698-706.
Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) versus cyclophosphamide, epirubicin, vincristine, prednisolone, ifosfamide, VP-16, methotrexate, dexamethasone (CEOP/IMVP-Dexa) for aggressive non-Hodgkinxxxs lymphoma. A multicenter randomized trial of the Austrian working party medical oncology.
Fridrik, MA, Hausmaninger, H, Greil, R, Lang, A, Drach, J, Fortelny, A, Krieger, O, Lin, W BLOOD. 1999, 94(10): 261B-261B.
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R, Egle A, Villunger A. Leuk Lymphoma. 1998 Nov,31(5-6):477-90.
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Blood. 1998 Jun 1,91(11):4273-81.
Inversion of CD4(+)/CD8(+) ratio in B chronic lymphocytic leukemia correlates with differential sensitivity of CD4(+) and CD8(+) T lymphocytes to the killing efficacy of Fas (APO-1/CD95) ligand(+) tumor cells.
Tinhofer, I, Marschitz, I, Kos, M, Henn, T, Egle, A, Villunger, A, Greil, R BLOOD. 1998, 92(10): 271B-271B.
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Cancer Res. 1997 Aug 15,57(16):3331-4.
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Geley S, Hartmann BL, Kapelari K, Egle A, Villunger A, Heidacher D, Greil R, Auer B, Kofler R. FEBS Lett. 1997 Jan 27,402(1):36-40.
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R. Blood. 1997 Jul 1,90(1):12-20.
Expression of Apo-1/Fas (CD95), Bcl-2 Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, GrГјnewald K, Greil R. Br J Haematol. 1997 May,97(2):418-28.
Fas (Apo-1/CD95) - Ligand expression on neoplastic plasma cells and its role for the expansion of the neoplastic clone.
Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T. Ann Hematol. 1997 Oct,75(4):135-40.
Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.
Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jäger G, LeMevel A, Najman A, Silingardi V, Spriano M, van Hoof A, Ehmer B. Blood. 1995 Dec 15,86(12):4446-53.
Necrotizing vasculitis associated with hepatitis C virus infection: successful treatment of vasculitis with interferon-alpha despite persistence of mixed cryoglobulinemia.
Extensive meningeal involvement as the primary manifestation of a systemic small lymphocytic lymphoma: favourable outcome after neuraxial irradiation without chemotherapy.
Soucek D, Ransmayr G, Twerdy K, Zwierzina H, Greil R, Fritsch E, Maier H, Pallua A, Gerstenbrand F. Br J Haematol. 1993 Apr,83(4):674-5.
A monoclonal antibody directed against the human intercellular adhesion molecule (ICAM-1) modulates the release of tumor necrosis factor-alpha, interferon-gamma and interleukin 1.
Geissler D, Gaggl S, Möst J, Greil R, Herold M, Dietrich M. Eur J Immunol. 1990 Dec,20(12):2591-6.
Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.
Thaler J, Denz H, Dietze O, Gastl G, Ho AD, Gattringer C, Greil R, Lechleitner M, Huber C, Huber H. Leuk Res. 1989,13(5):377-83.
Expression of leucocyte function-associated antigen-1 and 7F7-antigen, an adhesion molecule related to intercellular adhesion molecule-1 (ICAM-1) in non-Hodgkin lymphomas and leukaemias: possible influence on growth pattern and leukaemic behaviour.
In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: technical approach and comparison with results with anti-oncoprotein antibodies.
Greil R, Fasching B, Huber H. Lab Invest. 1989 Apr,60(4):574-82.
In situ quantification of T-cell subsets, NK-like cells and macrophages in Hodgkin's disease: quantity and quality of infiltration density depends on histopathological subtypes.
Receptors for the third component of complement: their association with maturation stage in non-Hodgkin lymphomas (NHL) and their possible implication with the development of follicular structures.
[Infiltration pattern of immunocompetent lymphocytes in the tissue of malignant non-Hodgkin's lymphoma: relationship to histological and clinical parameters].
Gattringer C, Radaszkiewicz T, Greil R, Pfaller W, Huber H. Wien Klin Wochenschr. 1985 Mar 1,97(5):258-63.